GRTX (Galera Therapeutics) Beneish M-Score : 0.00 (As of Dec. 13, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Galera Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Galera Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 7 years, the highest Beneish M-Score of Galera Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.

Galera Therapeutics Beneish M-Score Historical Data

The historical data trend for Galera Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galera Therapeutics Beneish M-Score Chart

Galera Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Get a 7-Day Free Trial

Galera Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Beneish M-Score	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Galera Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Galera Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galera Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galera Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Galera Therapeutics's Beneish M-Score falls into.

Galera Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Galera Therapeutics for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Jun24) TTM:

Last Year (Jun23) TTM:

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $11.96 Mil.
Total Assets was $16.38 Mil.
Property, Plant and Equipment(Net PPE) was $1.19 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.24 Mil.
Selling, General, & Admin. Expense(SGA) was $12.85 Mil.
Total Current Liabilities was $2.13 Mil.
Long-Term Debt & Capital Lease Obligation was $1.04 Mil.
Net Income was -4.064 + -4.381 + -5.587 + -15.073 = $-29.11 Mil.
Non Operating Income was -0.004 + 0 + -0.001 + -2.31 = $-2.32 Mil.
Cash Flow from Operations was -2.717 + -4.791 + -9.915 + -12.521 = $-29.94 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $42.00 Mil.
Total Assets was $48.28 Mil.
Property, Plant and Equipment(Net PPE) was $1.50 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.09 Mil.
Selling, General, & Admin. Expense(SGA) was $25.73 Mil.
Total Current Liabilities was $13.62 Mil.
Long-Term Debt & Capital Lease Obligation was $1.19 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (11.962 + 1.192) / 16.383)	/	(1 - (42.003 + 1.496) / 48.276)
	=	0.197095	/	0.098952
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.085 / (0.085 + 1.496))	/	(0.242 / (0.242 + 1.192))
	=	0.053763	/	0.168759
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(12.849 / 0)	/	(25.729 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((1.037 + 2.126) / 16.383)	/	((1.193 + 13.622) / 48.276)
	=	0.193066	/	0.306881
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-29.105 - -2.315	-	-29.944)	/	16.383
	=	0.192517

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Galera Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Galera Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Galera Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galera Therapeutics Inc (OTCPK:GRTX) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 134, Malvern, PA, USA, 19355

Website

https://www.galeratx.com

Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Executives

Mel Sorensen	director, officer: President and CEO	7 RAPPS RUN DRIVE, MALVERN PA 19355
Mark Bachleda	officer: Chief Commercial Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355
Chris Degnan	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Eugene P. Kennedy	officer: Chief Medical Officer	2503 SOUTH LOOP DRIVE, AMES IA 50010
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Jennifer Evans Stacey	officer: See Remarks	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Jon T Holmlund	officer: Chief Medical Officer
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Novo Holdings A/s	10 percent owner, other: SEE REMARKS	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joel F. Sussman	officer: Chief Accounting Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Sofinnova Venture Partners Ix, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Blackstone Clarus Gp L.p.	10 percent owner	C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154
Clarus Iv-a, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142